Cas No. 56616-91-2, Deucravacitinib intermediate

Deucravacitinib, a selective tyrosine kinase 2 inhibitor, presents a new frontier in the management of autoimmune diseases, including psoriasis, ulcerative colitis, and Crohn's disease. Our high-quality intermediates ensure a reliable supply of Deucravacitinib, supported by a seamless and optimized production process. Join forces with us to bring this game-changing treatment to patients worldwide, transforming the landscape of autoimmune disease management. Explore the possibilities with Deucravacitinib and make a difference in healthcare.